June 8, 2012
By launching fixed-dose combination drugs of its angiotensin II receptor blocker (ARB) Irbetan (irbesartan) with a calcium channel blocker (CCB) and a diuretic, Shionogi & Co. plans to enhance its family of irbesartan products and to boost its strength in...read more